G-Rich Oligonucleotides for Cancer Treatment
Oligonucleotides with guanosine-rich (G-rich) sequences often have unusual physical and biological properties, including resistance to nucleases, enhanced cellular uptake, and high affinity for particular proteins. Furthermore, we have found that certain G-rich oligonucleotides (GROs) have antiproliferative activity against a range of cancer cells, while having minimal toxic effects on normal cells. We have investigated the mechanism of this activity and studied the relationship between oligonucleotide structural features and biological activity. Our results indicate that the antiproliferative effects of GROs depend on two properties: the ability to form quadruplex structures stabilized by G-quartets and binding affinity for nucleolin protein. Thus, it appears that the antiproliferative GROs are acting as nucleolin aptamers. Because nucleolin is expressed at high levels on the surface of cancer cells, where it mediates the endocytosis of various ligands, it seems likely that nucleolin-dependent uptake of GROs plays a role in their activity. One of the GROs that we have developed, a 26-nucleotide phosphodiester oligodeoxynucleotide now named AS1411 (formerly AGRO100 or GRO26B-OH), is currently being tested as an anticancer agent in Phase II clinical trials.
KeywordsAptamer cancer G-rich oligonucleotides G-quartets quadruplex nucleolin
Acknowledgments and Disclosures
The work described herein was funded in part by the US National Cancer Institute and the US Department of Defense Prostate Cancer Program. In addition to these sources, the authors currently receive or have previously received funding from the Kentucky Lung Cancer Research Program, the Komen Breast Cancer Foundation, the University of Louisville, and Antisoma PLC (London, England). Paula J. Bates owns shares in Antisoma.
- 16.Girvan AC, Teng Y, Casson LK, Thomas SD, Jüliger S, Ball MW, Klein JB, Pierce WM Jr, Barve SS, Bates PJ. (2006) AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther 5:1790–9.PubMedCrossRefGoogle Scholar
- 18.Laber D, Bates P, Trent J, Barnhart K, Taft B, Miller D. (2005) Long term clinical response in renal cell carcinoma patients treated with quadruplex forming oligonucleotides. Clin Cancer Res 11:9088SGoogle Scholar
- 19.Miller D, Laber D, Bates P, Trent J, Taft B, Kloecker GH. (2006) Extended phase I study of AS1411 in renal and non-small cell lung cancers. Ann Oncol 17(Suppl 8):ix147–8.Google Scholar